Regencell Bioscience (NASDAQ:RGC) Sees Strong Trading Volume – Here’s Why

Shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC) saw unusually-strong trading volume on Monday . Approximately 776,339 shares were traded during trading, an increase of 84% from the previous session’s volume of 422,906 shares.The stock last traded at $25.37 and had previously closed at $20.54.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Regencell Bioscience Trading Up 31.0%

The company has a fifty day simple moving average of $16.14 and a two-hundred day simple moving average of $16.18.

Institutional Investors Weigh In On Regencell Bioscience

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC increased its position in Regencell Bioscience by 5,637.5% during the second quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock worth $6,664,000 after acquiring an additional 384,250 shares during the period. Squarepoint Ops LLC acquired a new stake in Regencell Bioscience in the 2nd quarter worth $1,701,000. BNP Paribas Financial Markets bought a new position in shares of Regencell Bioscience during the 2nd quarter worth about $768,000. XTX Topco Ltd bought a new position in shares of Regencell Bioscience during the 3rd quarter worth about $598,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Regencell Bioscience during the second quarter valued at about $222,000. 0.13% of the stock is currently owned by institutional investors.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.